Evotec SE

General information

Evotec SE
Essener Bogen 7
Manfred Eigen Campus
22419 Hamburg, Hamburg
Germany

Contact person: Susanne Kreuter, VP Head of Global Marketing
Company main phone: +49 (40) 560810
Company main fax: +49 (40) 56081222
Website: https://www.evotec.com

Year founded:	1993
Source of foundation:	Independent foundation
No. of employees:	Worldwide: 4788

Corporate description / mission:
Evotec SE is a company that specializes in drug discovery and development across a broad range of therapeutic areas, including neuroscience, oncology, metabolic diseases, infectious diseases, and inflammation. The company's product EVT894 is a fully human monoclonal antibody derived from a patient who was infected with the Chikungunya virus. The company's another product EVT 401 is a small molecule drug candidate and a potentially novel approach to orally treat inflammatory conditions such as Rheumatoid Arthritis.

State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 1999

Categorization

Sector:

Biotechnology - Therapeutics and Diagnostics

Subsector:

Anti-infectives
Antibodies
Biosimilars
Cell therapy
Gene therapy
Immunotherapy
Small molecules
Stem cells

Primary therapeutic areas:

Cardiovascular / cardiology
Congenital malformations, deformations and chromosomal abnormalities / medical genetics
Digestive system / gastroenterology
Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
Diseases of the eye / ophthalmology
Diseases of the nervous system / neurology
Endocrine, nutritional and metabolic diseases / endocrinology
Genitourinary system / Urology
Infectious and parasitic diseases / infectiology / parasitology
Musculoskeletal system and connective tissue / Orthopedics
Neoplasms / cancer / oncology
Pregnancy, childbirth and the puerperium / obstetrics
Respiratory / pulmonology
Skin and subcutaneous tissue / dermatology
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Business model:

Business incubation
In-licensing
Manufacturer
Out-licensing
R&D
Service company
Supplier / Distributor

Customer segments:

Large biotech & big pharma
Small biotech

Distribution:

Direct (own sales force)
Indirect (independent dealer)

Summary Products / Services / Technologies

Number of Biotech Products

Pre-clinical:	44
Phase I:	10
Phase II:	8
On the market:	2

Description of products:
EVT894
CNTX 6016
EVT801, etc.

Technology used:
iPSC platform

Financing details

Fiscal year (end of) 2025

Revenues:	USD 923.66M
R&D expenses:	USD 43.95M
Cash:	USD 490.33M

No. of shares:	177'594'029
Market cap. / valuation:	USD 960.40M

Collaborations & Clients

Partnering strategy / collaborations:
Carrick
Immunitas
Kazia Therapeutics
Recursion
BMS
Breakpoint Therapeutics, etc.